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INTRODUCTION 
Urinary stone disease has been known to affect humans since 
antiquity.  
The incidence of stone disease has shown migration with 
regard to site of stones from lower to upper. Also even though stone 
disease is two to three times more common in young adult males in 
comparison to females the gender divide is fast disappearing. 
The prevalence of renal stone disease is estimated to be 
varying around 1% to 15%.It was found that the prevalence in 
males is 10% and in females is 4% by Soucie et al1.The disease is 
more common in whites compared to Asians and Afro-Americans. 
The peak age incidence of stones is in the fourth to sixth 
decades of life. Stones are more common in hot arid climates, obese 
individuals and in those with sedentary life style. 
Hippocrates described the symptoms of renal colic as 
 “An acute pain is felt in the kidney, the loins, the flank and 
the testis of the affected side; the patient passes urine frequently; 
gradually the urine is suppressed. With the urine, sand is passed.” 
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The management of stone disease has also evolved in parallel 
to development in evaluation and imaging. Early open procedures 
have given way for less invasive endourological management with 
reduced morbidity and mortality. 
Percutaneous nephrolithotomy is considered the standard of 
care in the management of renal calculous disease. In the early days 
the procedure had considerable morbidity and at times mortality. 
With advances in technology and improved surgical technique 
the mortality is very low and morbidity has come down. Sepsis 
remains one of the dreaded complications of the procedure. We 
need factors to predict who all are more likely to develop sepsis so 
that we can aggressively manage those patients from the 
preoperative period itself and avert the dangerous complications 
from occurring. 
In this endeavour, analysis of both preoperative and 
intraoperative factors are essential to identify the risk factors since 
both can play a role in the development of sepsis. 
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AIM AND OBJECTIVE 
To analyse  prospectively the preoperative and intraoperative 
factors that predict the occurrence of systemic inflammatory 
response syndrome in patients undergoing percutaneous 
nephrolithotomy for renal calculus disease.  
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REVIEW OF LITERATURE 
The management of stone disease can be divided broadly into 
medical and surgical management. 
Medical management is done in patients with very minimal 
stone burden and who are asymptomatic. It is also useful in certain 
types of stones to prevent recurrence. 
In early days medical management didn’t find favour due to 
inadequate understanding of the basic pathogenesis of stone 
formation. 
With advances in technology and better understanding of the 
basic pathogenesis of stone formation, medical management has 
started playing increasing role in the management of stone disease. 
Also at the same time there is an intensely felt need to tackle the 
recurrence of stones inspite of successful surgical management of 
stone disease.  
Surgical management is the main stay of treatment in many 
patients. The evolution of surgical management of stone disease 
dates back to several centuries. 
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Ancient literatures point that surgical management was 
attempted with increasing vigour in the management of stone 
disease inspite of high morbidity and sometimes mortality. 
Eric Riches described the removal of urinary tract stones in 
Egypt as follows:  
 “The urethra was dilated by a wooden or cartilaginous 
cannula as thick as the thumb pushed in with great force alternating 
with blowing down the urethra; the stone was pressed down into the 
perineum by the fingers in the rectum until it could be reached from 
the urethra or sucked out by the mouth4”. 
MEDICAL MANAGEMENT 
The role of medical management of stone disease has evolved 
to the present state over the years. Scientific advances and better 
understanding of the pathophysiology of stone formation has helped 
in its development. 
Hence it is recommended that some form of medical 
management has to be recommended for all stone disease patients 
irrespective  of the etiology of the disease. 
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ROLE OF FLUID INTAKE  
The mainstay of this conservative approach is advice to 
achieve an urine output of 2 litres per day.This  increased urine 
output resulting in mechanical diuresis thereby preventing 
stagnation of urine and stone formation.It also results in formation 
of dilute urine  that alters the supersaturation of various stone 
forming components of urine3. 
Hosking et al described the so called “Stone clinic effect” in 
single stone formers which revealed that increasing fluid intake 
resulted in reduced recurrence rate 2. 
It was also found that type of water intake with regard to 
hardness of water did not play a significant role in predisposing to 
stone formation. 
Carbonated beverages particularly those acidified with citric 
acid was found to offer protection against stone formation. Juices 
containing citrate like lemonade and orange were also protective3. 
Various studies have concluded that it’s not the type of fluid 
ingested that is important but only the absolute amount of fluid 
matters. Hence it is advisable to take a intake of minimum 
3000ml/day to maintain output of 2500ml/day. 
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ROLE OF DIET 
Recent studies have thrown more light on the role of dietary 
modifications needed in stone disease prevention. The increasing 
stone disease prevalence in females can be explained by the 
predominant role played by diet. 
Increased animal protein consumption predisposes to stone 
formation. Studies have shown that four times higher incidence of 
stone diseases in northern and western India in comparison to 
eastern and southern parts is attributed to increased consumption of 
animal protein. Increased protein intake results in excess excretion 
of calcium ,uric acid and oxalate in urine predisposing to stone 
formation. 
Dietary sodium restriction is another important means of 
reducing stone recurrences5. High sodium consumption results in 
increased urinary levels of sodium, calcium and pH and decreased 
citrate level. The ultimate effect is increased crystallization of 
calcium in urine. Hence moderate sodium restriction will help in 
preventing recurrence8. 
Moderate intake of calcium is recommended in patients with 
calcium stone formation. Since severe restriction of calcium leads 
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to increased oxalate absorption resulting in calcium oxalate 
supersaturation calcium supplementation in moderate amounts is 
recommended7.The type of calcium being supplemented also 
matters in that calcium in the form of calcium citrate is more stone 
friendly supplement7. 
Avoiding oxalate and restricting vitamin c intake to less than 
2 gram per day are advised for those prone for oxalate stone 
formation.  
Selective medical treatment is more effective in preventing 
recurrence. It can be followed for certain specific types of stones. 
Selective therapy like citrate for hypocitraturic patients , increasing 
urinary pH by alkalinizing urine, agents to increase cystine 
solubility like mercaptopropionylglycine,D-penicillamine or 
captopril, urease inhibitor acetohydroxamic acid in infective stones 
and avoidance of drugs causing drug induced stones can be tried. 
Persons with increased body mass index have higher 
incidence of stone diseases .This propensity is more for females 
than males. Metabolic  syndrome has been shown by various 
studies to predispose to stone formation  
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SURGICAL MANAGEMENT 
Surgical management  of stone disease can be divided broadly 
into open procedures and endourological management. 
OPEN PROCEDURE 
French archer of Bagnolet  reported the first surgical attempt 
to remove renal stone. He claimed removal in a condemned 
individual who had a renal calculus. He was offered an incentive of 
being freed if he subjects himself to the crude procedure then. Its 
history that he got freed from both after his surgery in 1474. 
In 1550 Cardan of Milan operated on a teenage girl with 
lumbar abscess and removed 18 calculi which was documented. At 
that time the concensus was to operate only in patients with kidneys 
infected by calculous disease. 
In 1734 Lafite drained an abscess  through the loin. But the 
persistent drainage of pus made him to extend the original incision 
and he ultimately removed two calculi. He also treated a patient 
with urinary fistula due to renal calculous disease. He proposed that 
treating the underlying etiology will relieve the patient of his 
symptoms. 
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In 1872 William Ingalls explored the persistent fistula tract 
with a forceps and extracted a calculus from the kidney  being the 
first nephrolithotomy in Boston,USA.10 
In 1880 Henry Morris performed the first nephrolithotomy in 
England by removing a mulberry calculus. 
As the technique got evolved they tried to reduce the 
haemorrhagic complication by trying different incisions.In 1879 
Heineke popularized the pyelotomy incision which was favoured by 
all.The main drawback of the incision is its inability to extend the 
incison  for larger calculi to be extracted. 
Further attempts at reducing the complications led to the 
discovery of an avascular plane just posterior to the convex border 
of the kidney described by Josef Hyrtl, in 1882, and Max Brödel, in 
1902.It goes by the name “Brodels bloodless line or white line” 
(Schultheiss et al, 2000)8. 
Inspite of all the advances still complications occurred. 
ZuckerKandl demonstrated an extension of  pyelotomy incision into 
lower pole producing an inferior nephropyelolithotomy. Another 
innovation was a V incision into the poles. Other options tried were 
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control of vessels by hilar compression and innovative suturing 
techniques. 
In 1887 Czerny described an innovative suturing technique to 
control bleeding and also to reduce the development of  
pyelocutaneous fistula formation. 
Guyon described the ill effects of nephrectomy as treatment 
for calculous pyonephrosis  particularly in bilateral stone disease 
eventhough nephrectomy  is easier to perform in comparison to 
stone extraction. 
In 1889 Kummell performed the first nephron sparing surgery 
for stone disease .In 1913 Lower suggested pyelolithotomy is safer 
and easier method than nephrolithotomy. A study by Murphy et al  
in 1972 showed that there is no difference in recurrence rate 
between nephrolithotomy and pyelolithotomy contrary to popular 
belief then. Hence pyelolithotomy was the preferred procedure. 
Dees and Fox described removal of stones by using a 
coagulum made from combination of fibrinogen and thrombin. The 
coagulum was introduced into renal pelvis forming a cast of it. The 
risk of transmissible infection limited its use (Marshall, 
1983).Fischer et al in 1980 used cryoprecipitate as the source of 
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fibrinogen to form coagulum. It was safe and also easily 
available11.  
Landmark development in the management of stone disease 
by surgical approach is the description of  extended pyelolithotomy  
by Gil Vernet in 1965.This pioneering surgery became procedure of 
choice for large and complex calculi.It has wide application and 
acceptable minimal morbidity. It was further improved by 
combining with nephrotomies in radial directions if needed. 
Smith and Boyce in 1968 proposed  a procedure of 
approaching via an incision through the bloodless field.This 
procedure went by the name “ Anatrophic nephrolithotomy” since 
the procedure didn’t interfere with the blood supply to parenchyma 
and hence no atrophy of parenchyma.This permits successful stone 
removal ,restoration of calyceal anatomy and capsular integrity 
resulting in good preservation of renal function.Since morbidity of 
the open procedure remained a considerable problem the quest for 
better approach continued. 
ENDOUROLOGY IN STONE DISEASE 
Endourology was defined by Arthur Smith as “closed 
controlled manipulation within the genitourinary tract”.  
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In 1979 Wolf introduced the very first rigid endoscope for use 
in urology. 
The development of rod lens system by Harold Hopkins led to 
the creation of progressively smaller ureteroscopes with improved 
clarity and better working channels. 
Further developments in the field of endourology was 
heralded by the development of various energy sources used to 
fragment calculi intracorporeally. 
The foremost thing in the success  of  percutaneous 
nephrolithotomy is the gaining of access into the collecting system.  
Thomas Hillier in 1865 established the first therapeutic  
percutaneous nephrostomy (Bloom et al, 1989). 
PERCUTANEOUS NEPHROLITHOTOMY 
Following this development percutaneous access was utilized 
for calculous removal from the kidney by Swedish urologist B. 
Johannson and Fernstrom a radiologist,being  the first percutaneous 
nephrolithotomy in1973 and subsequently reported it in 197613. 
The original procedure was not a single step one as we do 
now. It was done over twenty days. Initially a  percutaneous access 
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tract to the pelvicalyceal system was established . A series of 
polypropylene semirigid dilators were warmed over steaming water 
to progressively increasing size. The final tract achieved was 20 Fr 
in size. They waited for two weeks for the tract to mature. They 
used a dormia basket to extract the calculus from the kidney. Thus 
the first successful percutaneous extraction of stone from kidney 
was done. But the time taken was too long and procedure was 
tedious for the patient and doctor. 
Pioneers in the field like Peter Alken, Michael Marberger, 
Wickham, Ronald. A.Miller, Joseph Segura and Ralph Clayman 
improved the way of accessing the pelvicalyceal system14.  
ACCESS TO THE COLLECTING SYSTEM  
A good knowledge about both renal and perirenal anatomy is 
vital in gaining an access which should be also both safe and 
useful. Variations in the anatomy particularly the mobility of 
kidney with respiration still poses challenges in obtaining an 
access. 
A thorough knowledge about the relative location of both 
kidneys in relation to vertebral bodies and their orientation and tilt 
in relation to the spine are essential for success. 
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The real risk to the pleura and sometimes the lung 
particularly in gaining access to the upper calyceal system should 
be kept in mind. 
There exists risk to the colon particularly in patients with 
retro renal colon. It is more common in the left side in thin 
individuals particularly females. 
The collecting system anatomy is also equally important for 
successful access. The outermost part of collecting system is minor 
calyx. This minor calyx join to form major calyx which drains into 
the pelvis through infundibulum. This infundibular part may be a 
limitation in patients with narrowing in gaining access into the 
pelvis15. 
The minor calyx draining a single papilla are called simple 
whereas those draining more than one papilla are complex 
.Complex calyces are more common in poles. Also the simple 
calyces are oriented in two rows located either anteriorly or 
posteriorly.15 
The orientation of these calyces is important to determine the 
best access tract. The anteroposterior orientation also varies with 
side. 
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There are two types of orientations described. In the Brodel 
type the posterior calyces form an angle of 20 degree with the 
frontal plane meaning posterior calyces are lateral. In the Hodson 
type the posterior calyx form an angle of 70 degree with the frontal 
plane meaning posterior calyces are medial. 
   Brodel type is more common in the right side while Hodson 
type is more common in the left side. 
   Extensive studies have shown that posterior calyceal 
puncture through the fornix is the ideal site for entry to gain access 
with minimal complications. So the preferred  approach is through 
the posterior calyx and the level being decided by the location of 
the calculus within the kidney. Subcostal access is the safest level 
to enter.16 
ROUTES OF ACCESS 
Gaining access into the upper tract collecting system can be 
achieved by both antegrade and retrograde methods. Antegrade 
access is indicated in performing procedures like percutaneous 
endopyelotomy  endoureterotomy  nephrolithotomy,  calyceal 
diverticula,hydrocalyces, and antegrade ureteroscopic treatment of 
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large ureteral stones, percutaneous resection of urothelial tumors  
and management of fungal bezoars. 
ANTEGRADE ACCESS  
Antegrade access is the standard of approach for establishing 
a percutaneous tract. 21 G or 18 G needle is inserted into the 
collecting system under either fluoroscopic or ultrasonic guidance. 
Guidewire  is passed into the system. 
The tract is established by dilating using rigid metal dilators 
introduced by Alken .These coaxial stainless steel dilators are 
passed over a rigid guide rod.The ball tip prevents overshooting of 
dilators. It is especially suitable for patients with dense fibrous 
tissue surrounding the kidney. It also causes more trauma to 
surrounding tissue. 
Other option is polyurethane semirigid Amplatz dilators. The 
dilatation is done in increments of 2 Fr and the dilator has to be 
removed before inserting the next higher dilator. The advantage is 
lesser trauma to tissues. But disadvantage is risk of bleeding when 
everytime dilator is pulled out for next insertion.17 
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To overcome the difficulties with these two methods balloon 
dilators came into use .But balloon dilators are expensive. Also 
they are less useful in densely scarred tissue. 
Recently single step dilatation techniques are available using 
semi rigid plastic dilator, rigid dilator with sheath and balloon 
dilator with an expandable sheath.18 
Antegrade access is established under ultrasonographic or 
fluoroscopic guidance.19 Even today blind puncture is being 
practiced. 
Access under ultrasonography guidance was introduced by 
Pedersen in 1974.Advantages include use of portable machines and 
absence of radiation .Disadvantages are operator dependability, 
difficulty visualizing the needle and further monitoring being 
difficult. 
Fluoroscopic guidance is commonly used. Two different 
methods are “eye of the needle” technique and “triangulation 
technique”.20 
RETROGRADE ACCESS 
Retrograde access is helpful in obese patients, anomalously 
located kidneys and hypermobile kidneys. Retrograde transurethral 
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access is established by placing a 5 or 6 Fr ureteric catheter. 
Contrast is injected into the pelvicalyceal system to delineate and 
dilate the system.  Guidewire is introduced into the system and can 
be brought out through the percutaneous tract by grasping it with 
the nephroscope. 
Ureteroscope can also be used to establish a tract with 
retrograde assistance. 
POSITIONING OF PATIENT 
Proper positioning of patient for the procedure is vital. Prone 
position was initially used by Goodwin in 1955 in creating 
percutaneous access. Commonly the prone position is preferred 
since posterior calyceal puncture is easier in this position. Also it 
provides a wider area of access and a stable work surface. 
Disadvantages include decrease cardiac index, diminished 
pulmonary capacity if not padded properly, neuromusculoskeletal 
complications, ocular injury ,rhabdomyolysis and difficulty 
controlling the airway.21 
To overcome this difficulty supine position was introduced by 
Valdivia Uria in 1987. Anterior calyces were entered through a 
lateral or anterolateral approach.22 
 20 
Advantages are the access sheath angle is horizontal allowing 
fragments to wash out due to reduced pressure within the collecting 
system. Also no repositioning is required during the procedure with 
easier access to the urethra. 
Disadvantages are unfamiliar procedure, low collecting 
system pressure and hence poor visualization .Also upper pole 
access in supine position is difficult. 
Other variations in position like supine with same side 
elevation, supine with same side flank elevation and asymmetry 
lithotomy position and flank position. 
Following successful fragmentation and retrival of stones a 
nephrostomy is kept along with a ureteral stent or catheter. Now 
tubeless procedure in the form of not keeping a nephrostomy in 
patients in whom complete clearance has been achieved is being 
done.25 Still one step ahead is totally tubeless in which ureteric 
stent also is avoided.26 
In order to prevent development of infectious complications a 
preoperative   sterile urine is always optimal .But this may be difficult 
to achieve in certain situations like abnormality in anatomy,  recent 
hospitalization, other infective foci in the body and  patients already 
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on catheter. They require urine culture and appropriate treatment. It is 
standard practice to do urine culture in patients with staghorn calculus 
and those on percutaneous drainage catheter. In all other situations a 
urine analysis is adequate.  Culture is required if analysis is abnormal. 
A full course of antibiotics is given when culture is positive. The 
American Urological Association recommends periprocedural 
antimicrobial prophylaxis for all cases of percutaneous renal surgery 
(Wolf et al, 2008).23 
Nonrandomized trials show a  infection rate of 35% to 40% if 
no antimicrobial prophylaxis is  used compared with 0% to 17% if 
prophylaxis is used (Charton et al,1986; Darenkov et al, 1994).24 
Prophylaxis recommended include first or second generation 
cephalosporins along with aminoglycosides which can be replaced 
with aztreonam in situations of elevated renal parameters. In 
addition either metronidazole or clindamycin or a fluoroquinolone 
can be added. 
In case of prophylaxis a course for one day is advised. 
COMPLICATIONS OF PERCUTANEOUS  
NEPHROLITHOTOMY 
Even though percutaneous nephrolithotomy is a very effective 
procedure in treating calculous disease it is not without 
complications. 
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Haemorrhage is the most common complication of 
percutaneous surgery. 0.5 -4% of patients require blood transfusion 
following percutaneous nephrostomy alone due to haemorrhage.27 
When percutaneous nephrolithotomy was also done it increased to 6 
-20%.18 
Mostly the source of haemorrhage is from parenchymal 
vessels. Intraoperatively the access sheath acts as a  tamponade 
.Post procedure if there is bleeding it is better to insert and keep the 
nephrostomy tube occluded. Also we can compress the incision and 
remove the clots from the collecting system.  If still not controlled 
it requires selective angio embolization.28  
1% of patients develop delayed haemorhage which is mainly 
due to arterio venous fistulas or pseudoaneurysms. Angiography 
and selective embolization is needed to treat them. 
Recently placement of endovascular stent across the bleeding 
vessel and injection of thrombin or tissue adhesive under 
ultrasonographic guidance have been tried with success.29 
Collecting system injury like pelvic perforation can occur. It 
is identified by sudden collapse of renal pelvis. It can lead to 
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massive extravasation of fluid. The procedure is stopped with both 
nephrostomy and ureteral stent being placed.30 
Visceral injury to colon,duodenum and jejunum can occur. 
Extraperitoneal colonic injury are managed conservatively by 
prompt and separate drainage of colon and kidney.31 Intraperitoneal 
injury needs to be repaired. Liver and splenic injuries are very rare. 
Pleural and lung injuries can occur particularly when 
supracostal access is being done. When identified they require a 
costal drainage.32  
Metabolic and electrolyte imbalances can occur when normal 
saline used for irrigation gets extravasated. Venous gas embolism 
can occur which is fatal. 
Post procedure fever can occur in 15 -30% of patients. Inspite 
of antibiotic prophylaxis systemic inflammatory response syndrome 
occurs. 1-2 % of these patients develop frank sepsis. 
Studies have shown that treating bladder culture alone is not 
sufficient in preventing sepsis. Sepsis have occurred in patients 
with preoperative urine culture showing no growth. 
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It is not possible to predict which of the febrile patients 
progress to sepsis. Hence there is a need to predict who all will 
develop systemic inflammatory response syndrome and thus by 
treating them with appropriate full course of antibiotics we can 
prevent the development of sepsis in these patients undergoing 
percutaneous nephrolithotomy.33 
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MATERIALS AND METHODS 
TITLE OF STUDY 
To identify preoperative and intraoperative  factors that 
influence development of Systemic Inflammatory Response  
Syndrome (SIRS) following  Percutaneous  Nephrolithotomy 
(PCNL). 
PERIOD OF STUDY 
APRIL 2012 TO MARCH 2013. 
STUDY DESIGN 
Prospective study 
PLACE OF STUDY 
Department of Urology, Madras Medical College, Chennai. 
ETHICAL CLEARANCE 
The Institutional Ethics Committee of our college approved 
the study. No -12042012. 
INCLUSION CRITERIA 
All patients with renal stone disease who underwent 
Percutaneous Nephrolithotomy in our Institution. 
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EXCLUSION CRITERIA 
1) Patients with infected collecting system. 
2) Patients with synchronous ureteric stones 
3) Patients on stents or PCN drainage. 
METHOD OF STUDY    
All  patients who presented to our Department with renal 
stone disease were evaluated with physical examination, urine 
analysis, urine culture and sensitivity , complete blood count , renal 
function test , X ray KUB, and Plain and contrast enhanced 
computerised tomography. 
All patients were subjected to Percutaneous nephrolithomy 
after obtaining anaesthetic fitness. 
All patients were administered 1 gm of ceftriaxone and 500 
mg of amikacin as standard antibiotic prophylaxis for a period of 
three days including one preoperative dose. Patients with 
preoperative serum creatinine greater than 1.4 were not 
administered amikacin. 
All patients underwent PCNL under general anaesthesia. 
Patients were placed in lithotomy position and a 5 Fr ureteric 
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catheter was introduced. Contrast was used to identify the 
collecting system and to select the calyx for puncture. 
After prone positioning with adequate padding posterior 
calyceal puncture was done under fluoroscopic guidance. Level of 
puncture was decided as per location of stone to ensure complete 
clearance. 
Puncture was done using 18 G three part needle and guide 
wire was placed within the system. Guide rod was introduced  and 
serial coaxial dilatation of tract done with Alkens metal dilator. 
Amplatz sheath was placed. Using 26 Fr  Karl Storz nephroscope 
and Karl Storz pneumatic lithotripter stone fragmentation was done. 
After fragments were evacuated antegrade 4 Fr ureteric stent 
is placed. A 20 Fr nephrostomy tube it also placed. 
Intraoperative parameters like operative time,no of access 
tracts used and need for blood transfusion were recorded. Pelvic 
urine collected on puncture and stone were sent for culture and 
sensitivity. 
Patients were followed up in postop period with daily 
complete blood count including White blood cell count, serial pulse 
rate, temperature and respiratory rate monitoring. 
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Post procedure check Xray KUB was taken before removing 
the nephrostomy tube in the first postoperative day. Ureteric stent 
was removed after 14 days. 
Patients who developed any two or above of the following in 
the postoperative period were considered to have developed 
systemic inflammatory response syndrome (SIRS). 
1) Temperature   >100.40 F (380 C) or < 96.80 F (360C). 
2) Pulse rate > 90/min. 
3) Respiratory rate >20/min. 
4) WBC count >12000/ml or < 4000/ml. 
STATISTICAL ANALYSIS OF THE STUDY 
For discrete data proportion are computed and the mean and 
standard deviation are computed for the continuous data. The chi 
square test was applied to compare the proportions between the 
groups. To examine the association between the outcome (SIRS) 
and several variables logistic regression analysis was done.  All 
analyses were two tailed and p <0.05 was considered significant. 
Statistical package for social sciences (SPSS) version 16.0 was 
used for data analysis.  
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OBSERVATION AND RESULTS 
DESCRIPTIVE STATISTICS 
A total of 120 patients underwent Percutaneous 
Nephrolithotomy in our Institute during the study period . All  the 
patients were evaluated both preoperatively and postoperatively as 
described above. Of these 120 patients 29(24.1%) of them 
developed features of systemic inflammatory response syndrome in 
the postoperative period. 
The patient characteristics are shown as below. 
FREQUENCIES 
Table-1 :Showing basic characteristics of study population. 
  Age Sr. Creatinine 
Stone 
size 
OP 
time 
No of 
tracts 
Valid 120 120 120 120 120 N 
Missing 0 0 0 0 0 
Mean 42.18 1.196 2.893 70.32 1.10 
Std. 
Deviation 11.794 .6076 .5264 19.516 .301 
Minimum 18 .6 2.2 40 1 
Maximum 65 3.4 5.1 125 2 
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GENDER OUTCOME 
Tab-2: Gender distribution Crosstab 
outcome_gp 
   
No SIRS SIRS 
Total 
Count 56 17 73 Male 
% within sex 76.7% 23.3% 100.0% 
Count 35 12 47 
sex 
Female 
% within sex 74.5% 25.5% 100.0% 
Count 91 29 120 Total 
% within sex 75.8% 24.2% 100.0% 
 
Fig 1. Gender  distribution.
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Tab-3: Gender distribution analysis Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square .079a 1 .779 
  
Continuity 
Correctionb .004 1 .951 
  
Likelihood Ratio .078 1 .780   
Fisher's Exact Test    .829 .472 
Linear-by-Linear 
Association .078 1 .780 
  
N of Valid Casesb 120     
a. 0 cells (.0%) have expected count less than 5. The 
minimum expected count is 11.36.                          
b. Computed only for a 2x2 table 
In this study of 120 patients 73 (60.8%) of them were males and 
47 (39.2%) were females(fig 1).. Among the males 17(23.3%)developed 
SIRS and  56 (76.7%)  didn’t develop SIRS. Among the females 12 
(25.5%) developed SIRS and 35 (74.5%) didn’t develop SIRS(tab 2). 
On statistical analysis using Chi square test it was found that 
the gender distribution between those who developed SIRS  and 
those who didn’t develop was not statistically significant  
(p= 0.829)(tab 3). 
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DIABETES MELLITUS  
Tab-4: Distribution of diabetes mellitus Crosstab 
   outcome_gp 
   No SIRS SIRS 
Total 
Count 23 13 36 Yes 
% within DM 63.9% 36.1% 100.0% 
Count 68 16 84 
DM 
No 
% within DM 81.0% 19.0% 100.0% 
Count 91 29 120 Total 
% within DM 75.8% 24.2% 100.0% 
 
 Fig 2. SIRS in diabetes mellitus.
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Tab-5: Analysis of SIRS and Diabetes mellitus Chi-Square Tests 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square 4.004a 1 .045 
  
Continuity 
Correctionb 3.127 1 .077 
  
Likelihood Ratio 3.825 1 .050   
Fisher's Exact 
Test 
   .062 .041 
Linear-by-Linear 
Association 3.970 1 .046 
  
N of Valid Casesb 120     
a. 0 cells (.0%) have expected count less than 5. The 
minimum expected count is 8.70. 
b. Computed only for a 2x2 table  
In this study the number of patients who had diabetes mellitus 
was 36 (30%) and 84(70%) didn’t have diabetes mellitus. Of the 
patients who developed SIRS 13 (36.1%)  had diabetes mellitus and  
16 (19%) didn’t have diabetes mellitus(tab 4)(fig 2). 
The proportion of patients who developed SIRS was found to 
be relatively higher in those who had diabetes mellitus compared to 
non diabetics. But the difference between them was statistically 
insignificant (p=0.062)(tab 5). 
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BLADDER URINE CULTURE 
Tab-6: Bladder urine culture Crosstab 
   outcome_gp 
   No SIRS SIRS 
Total 
Count 42 18 60 Growth 
% within BU_CS 70.0% 30.0% 100.0% 
Count 49 11 60 
BU_CS 
Sterile 
% within BU_CS 81.7% 18.3% 100.0% 
Count 91 29 120 Total 
% within BU_CS 75.8% 24.2% 100.0% 
 
Fig 3 SIRS and Bladder urine culture
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Tab-7: Analysis of bladder urine culture Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square 2.228a 1 .136 
  
Continuity 
Correctionb 1.637 1 .201 
  
Likelihood Ratio 2.245 1 .134   
Fisher's Exact Test    .200 .100 
Linear-by-Linear 
Association 2.210 1 .137 
  
N of Valid Casesb 120     
a. 0 cells (.0%) have expected count less than 5. The 
minimum expected count is 14.50. 
b. Computed only for a 2x2 table 
  Bladder urine culture done preoperatively showed growth in 
60 (50%) patients and 60 (50%) had sterile urine. Of the 60 patients 
who had growth 18 (30%) developed SIRS and 11 (18.3%) with 
sterile urine developed SIRS (tab 6)(fig 3). 
  The proportion of patients who developed SIRS in those 
with growth in the bladder urine culture when compared with those 
with sterile urine was statistically insignificant ( p= .200)(tab 7). 
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BLOOD TRANSFUSION  
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Fig 4. Blood transfusion and SIRS. 
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Tab-8: Blood transfusion Crosstab 
outcome_gp 
   
No 
SIRS SIRS 
Total 
Count 7 8 15 Yes 
% within 
bld_transfus 46.7% 53.3% 100.0% 
Count 84 21 105 
Bloodtransfusion 
No 
% within 
bld_transfus 80.0% 20.0% 100.0% 
Count 91 29 120 Total 
% within 
bld_transfus 75.8% 24.2% 100.0% 
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Tab-9: Analysis of Blood transfusion Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square 7.958a 1 .005 
  
Continuity 
Correctionb 6.243 1 .012 
  
Likelihood Ratio 6.906 1 .009   
Fisher's Exact Test    .009 .009 
Linear-by-Linear 
Association 7.891 1 .005 
  
N of Valid Casesb 120     
a. 1 cells (25.0%) have expected count less than 5. The 
minimum expected count is 3.63. 
b. Computed only for a 2x2 table 
In this study the no of patients who received blood 
transfusion were 15 (12.5%). Of these patients 8 (53.3%) developed 
SIRS. 21 (20%) patients who didn’t receive blood transfusion 
developed SIRS (tab 8) (fig 4). 
On analysis it was found that the association between the patients 
who had blood transfusion and developed SIRS in comparison to those 
who didn’t receive transfusion was statistically significant (p=.009) (tab 9). 
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 NO OF ACCESS TRACTS  
Tab-10: No of access tracts Crosstab 
outcome_gp 
   
No SIRS SIRS 
Total 
Count 87 21 108 1 
% within No 
tracts 80.6% 19.4% 100.0% 
Count 4 8 12 
No tracts 
2 
% within No 
tracts 33.3% 66.7% 100.0% 
Count 91 29 120 Total 
% within No 
tracts 75.8% 24.2% 100.0% 
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Fig-5 No. of access tract and SIRS 
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Tab-11: Analysis of No of tracts Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square 13.141a 1 .000 
  
Continuity 
Correctionb 10.691 1 .001 
  
Likelihood Ratio 11.040 1 .001   
Fisher's Exact 
Test 
   .001 .001 
Linear-by-Linear 
Association 13.032 1 .000 
  
N of Valid Casesb 120     
a. 1 cells (25.0%) have expected count less than 5. The 
minimum expected count is 2.90. 
b. Computed only for a 2x2 table 
In this study the no of patients who had one access tract were 
108 (90%) and those who had two tracts were 12 (10%). Of those 
with one tract 21 (19.4%) developed SIRS. In patients with two 
tracts 8 (66.7%) developed SIRS (tab 10). 
On statistical analysis the proportion of patients developing 
SIRS was significant (P=.001) in those with two tract access when 
compared with those with single tract (tab 11) (fig 5). 
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PELVIC URINE CULTURE 
Tab-12: Pelvic urine culture Crosstab 
outcome_gp 
   
No SIRS SIRS 
Total 
Count 22 20 42 Growth 
% within PU_CS 52.4% 47.6% 100.0% 
Count 59 19 78 
PU_CS 
Sterile 
% within PU_CS 75.6% 24.4% 100.0% 
Count 81 39 120 Total 
% within PU_CS 67.5% 32.5% 100.0% 
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Fig 6- Pelvic urine culture and SIRS 
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Tab-13: Analysis of pelvic urine cultureChi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square .004a 1 .0647 
  
Continuity 
Correctionb .000 1 .0684 
  
Likelihood Ratio .005 1 .0946   
Fisher's Exact Test    .0467 .0567 
Linear-by-Linear 
Association .004 1 .0947 
  
N of Valid Casesb 120     
a. 0 cells (.0%) have expected count less than 5. The 
minimum expected count is 10.15. 
b. Computed only for a 2x2 table 
In this study pelvic urine culture was positive in 42 (35%) 
patients. Of these patients 20(47.6%) developed SIRS. In patients 
with no growth in pelvic urine 19(24.4%) developed SIRS(tab 
12)(fig 6). 
On analysis it was found that those with pelvic urine culture 
positive developed SIRS more incomparison to those with sterile 
pelvic urine culture which was found to be statistically significant 
(p=0.0467).(tab 13). 
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STONE CULTURE 
Tab-14: Stone culture Crosstab 
outcome_gp 
   
No SIRS SIRS 
Total 
Count 22 19 41 Growth 
% within stone_CS 53.7% 46.3% 100.0% 
Count 61 18 79 
stone_CS 
Sterile 
% within stone_CS 77.2% 22.8% 100.0% 
Count 83 37 120 Total 
% within stone_CS 69.16% 30.84% 100.0% 
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Fig 7- Stone culture and SIRS 
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Tab-15: Analysis of stone culture Chi-Square Tests  
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-
Square .241a 1 .624 
  
Continuity 
Correctionb .071 1 .790 
  
Likelihood Ratio .238 1 .625   
Fisher's Exact Test    .0389 .0391 
Linear-by-Linear 
Association .239 1 .625 
  
N of Valid Cases 120     
a. 0 cells (.0%) have expected count less than 5. The 
minimum expected count is 9.91. 
b. Computed only for a 2x2 table 
In this study 41(34.16%) patients showed growth in stone culture 
of which 19(46.3%) developed SIRS. 18 (22.8%) patients developed 
SIRS who showed no growth in stone culture(tab14) (fig 7). 
On analysis it was found that the proportion of patients who 
developed SIRS is significant (p=0.0389) in patients with stone 
culture growth in comparison to those who had no growth in stone 
culture(tab 15). 
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Tab-15 a: Analysis of bladder, pelvic and stone cultures 
 
BLADDER 
URINE 
CULTURE 
PELVIC 
URINE 
CULTURE 
STONE 
CULTURE 
No of cases 60/120 42/120 41/120 
ORGANISM No SIRS SIRS 
NO 
SIRS SIRS 
NO 
SIRS SIRS 
1.E.Coli 
2.Proteus 
3.Klebsiella 
4.Pseudomonas 
5.staphylococcus 
16 
9 
4 
6 
7 
6 
8 
2 
1 
1 
9 
8 
4 
3 
3 
6 
5 
- 
2 
2 
3 
8 
2 
5 
4 
2 
7 
1 
5 
4 
Total 42 18 27 15 22 19 
In our study the number of patients who had growth in the 
preoperative bladder urine culture was 60 (50%). In case of pelvic 
urine culture 42 out of 120 (35%) had growth in the culture. In case 
of stone culture 41 out of 120 (34%) had growth in the culture. 
On analysis it was found that the association between bladder 
urine culture and SIRS was statistically insignificant. 
Univariate analysis revealed significant association between 
pelvic urine and stone culture with occurrence of SIRS.  
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SERUM CREATININE 
Tab-16: Sr Creatinine Cross tabulation 
   Outcome gp 
   No SIRS SIRS 
Total 
Count 11 7 18 Abnormal 
(>1.4) 
% within sr 
creat gp 61.1% 38.9% 100.0% 
Count 80 22 102 
Sr. creatinine 
gp 
Normal 
(<=1.4) 
% within sr 
creat gp 78.4% 21.6% 100.0% 
Count 91 29 120 Total 
% within sr 
creat gp 75.8% 24.2% 100.0% 
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Tab-17: Analysis of serum creatinine Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square 2.505a 1 .114 
  
Continuity 
Correctionb 1.649 1 .199 
  
Likelihood Ratio 2.297 1 .130   
Fisher's Exact Test    .137 .102 
Linear-by-Linear 
Association 2.484 1 .115 
  
N of Valid Casesb 120     
a. 1 cells (25.0%) have expected count less than 5. The 
minimum expected count is 4.35. 
In this study 18 (15%) patients had elevated serum creatinine 
value .Of which 7 (38.9%) patients developed SIRS(tab16). On 
analysis the proportion of patients who developed SIRS with 
elevated serum creatinine in comparison to those with normal 
serum creatinine was statistically insignificant (p=0.137)(tab 17). 
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AGE DISTRIBUTION 
Tab-18: Age distribution Crosstab 
outcome_gp 
   
No SIRS SIRS 
Total 
Count 45 7 52 <42yrs 
% within age gp 86.5% 13.5% 100.0% 
Count 46 22 68 
Age gp 
>=42yrs 
% within age gp 67.6% 32.4% 100.0% 
Count 91 29 120 Total 
% within age gp 75.8% 24.2% 100.0% 
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Tab-19: Age analysis Chi-Square Tests 
 Value df 
Asymp. 
Sig.  
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 5.738a 1 .017   
Continuity 
Correctionb 4.754 1 .029 
  
Likelihood Ratio 6.019 1 .014   
Fisher's Exact Test    .019 .013 
Linear-by-Linear 
Association 5.690 1 .017 
  
N of Valid Casesb 120     
a. 0 cells (.0%) have expected count less than 5. The 
minimum expected count is 12.57. 
b. Computed only for a 2x2 table. 
In this study the age distribution showed average age of 42 
yrs(tab18). On analysis the proportion of patients developing SIRS 
was statistically significant in comparison between those aged 
above 42 yrs and below 42 years (p=0.019).(tab 19). 
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STONE SIZE 
Tab-20: Stone size Crosstab 
outcome_gp 
   
No SIRS SIRS 
Total 
Count 69 11 80 <2.893 
cms 
% within stone gp 86.2% 13.8% 100.0% 
Count 22 18 40 
Stone gp 
>=2.893  
cms 
% within stone gp 55.0% 45.0% 100.0% 
Count 91 29 120 Total 
% within stone gp 75.8% 24.2% 100.0% 
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Fig 8- Stone size and SIRS 
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Tab-21: Analysis Stone size Chi-Square Tests 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-Square 14.210a 1 .000   
Continuity 
Correctionb 12.556 1 .000 
  
Likelihood Ratio 13.603 1 .000   
Fisher's Exact Test    .000 .000 
Linear-by-Linear 
Association 14.092 1 .000 
  
N of Valid Casesb 120     
a. 0 cells (.0%) have expected count less than 5. The 
minimum expected count is 9.67. 
b. Computed only for a 2x2 table 
In this study the average stone size was 2.893 cms. The 
proportion of patients who developed SIRS in patients with stone 
size <2.893 cms was 11(13.8%)(tab 20)(fig 8). In the other group 
with stone size > 2.893 cms the number of patients who developed 
SIRS was 18(45%). On statistical analysis the proportion of 
patients developing SIRS when stone size > 2.893 cms was 
statistically significant (tab 21) when compared with those who had 
stone size < 2.893 cms. 
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OPERATIVE TIME 
Tab-22: Operative time Crosstab 
Outcome gp 
   
No SIRS SIRS 
Total 
Count 63 11 74 <70.32 mts 
% within optime 
gp 85.1% 14.9% 100.0% 
Count 28 18 46 
Optime gp 
>=70.32mts 
% within optime 
gp 60.9% 39.1% 100.0% 
Count 91 29 120 Total 
% within optime 
gp 75.8% 24.2% 100.0% 
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Tab-23: Analysis of Operative time Chi-Square Tests 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square 9.114a 1 .003 
  
Continuity 
Correctionb 7.838 1 .005 
  
Likelihood Ratio 8.927 1 .003   
Fisher's Exact 
Test 
   .004 .003 
Linear-by-Linear 
Association 9.038 1 .003 
  
N of Valid Casesb 120     
a. 0 cells (.0%) have expected count less than 5. The 
minimum expected count is 11.12. 
b. Computed only for a 2x2 table 
In this study the average operative time was 70.32 minutes. 
11(14.9%) developed SIRS in the group with operative time <70.32 
mins. In the group with operative time > 70.32 mins, 18(39.1%) 
patients developed SIRS (tab22). 
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On statistical analysis the proportion of patients developing 
SIRS in those with operative time >70.32 mins is statistically 
significant (p=0.004) in comparison with those with operative time 
<70.32 mins.(tab23). 
On univariate analysis gender,diabetes mellitus ,bladder urine 
culture and serum creatinine were found to be statistically 
insignificant. 
Blood transfusion, no of access tracts, pelvic urine culture, 
stone culture, stone size, age and operative time were found to be 
statistically significant. 
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LOGISTIC REGRESSION 
Tab-24: Categorical Variables Codings 
  Frequency Parameter coding (1) 
<70.32 mts 74 .000 Op time_ 
>=70.32mts 46 1.000 
Growth 60 1.000 BU_CS 
Sterile 60 .000 
Yes 15 1.000 Bld_transfus 
No 105 .000 
Growth 42 1.000 PU_CS 
Sterile 78 .000 
Growth 41 1.000 stone_CS 
Sterile 79 .000 
Abnormal(>1.4) 18 1.000 sr_creat_ 
Normal(<=1.4) 102 .000 
<2.893 cms 80 .000 stone_size 
>=2.893 cms 40 1.000 
<42yrs 52 .000 age 
>=42yrs 68 1.000 
Yes 36 1.000 DM 
No 84 .000 
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Tab-25: Variables in the Equation 
95.0% 
C.I.for 
EXP(B)   B S.E. Wald df Sig. Exp(B) 
Lower Upper 
DM(1) .481 .598 .647 1 .421 1.618 .501 5.229 
BU CS(1) .364 .531 .469 1 .493 1.439 .508 4.077 
Bld transfus(1) 1.368 .764 3.202 1 .074 3.927 .878 17.564 
PU CS(1) -.086 .561 .024 1 .878 .917 .305 2.756 
Stone CS(1) -.958 .658 2.120 1 .045 .384 .106 1.393 
Sr creat gp(1) .385 .756 .259 1 .611 1.470 .334 6.471 
Age gp(1) .842 .604 1.944 1 .163 2.321 .711 7.582 
Stonesize 
gp(1) 1.498 .509 8.672 1 .003 4.473 1.650 12.124 
Optime gp(1) 1.268 .542 5.475 1 .019 3.552 1.228 10.271 
Step 
1a 
Tract  -
3.238 .650 24.828 1 .000 .039 
  
a. Variable(s) entered on step 1: DM, BU_CS, bld transfus, 
PU CS, stone CS, sr craeat gp, age gp, stone gp, optime gp. 
On multivariate regression analysis stone size, no of access 
tracts, operative time and stone culture were found to be 
statistically significant (Table 24,25) with regard to occurrence of 
SIRS. 
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DISCUSSION 
Renal stone disease is a common urological problem. Medical 
management may not be possible in all situations . In certain 
situations like increasing stone burden or in specific type of stones 
like infective stones surgical management is warranted. Moreover 
medical management is more useful to prevent recurrences 
following surgical removal rather than as primary therapy. 
Surgical management as described includes both open and 
endourological procedures. In the modern era of minimally invasive 
surgery renal calculous surgery is no exception. 
The procedure of Percutaneous nephrolithotomy has gained 
wide spread acceptance and is the standard of care to treat renal 
calculous disease. 
The procedure when attempted initially was time consuming, 
tedious for both patient and treating surgeon and with considerable 
morbidity and some mortality. 
With advances in imaging, optics and improved 
understanding of the pathology behind the considerable morbidity  
the procedure has been standardized . 
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Initially obtaining an access was considered a vital step in the 
success of the procedure.  
With good preoperative imaging particularly reconstructed 
computerised tomography, it paved way for better localization and 
defining the extent of calculi. Also better delineation of 
pelvicalyceal anatomy has helped us in obtaining an access to the 
pelvicalyceal system with ease. 
Further understanding of the way of obtaining an access with 
both fluoroscopic and ultrasonographic guidance has helped us in 
successfully creating a tract into the pelvicalyceal system. 
Even though both antegrade and retrograde techniques of 
access are available, the most commonly practised access is through 
the antegrade access. 
Developments in creating a tract sufficient for the procedure 
has also lended a helping hand in the success of the procedure. 
Various methods of tract dilatation like coaxial  Alken dilators, 
Amplatz semi rigid dilators and balloon dilators have helped in 
establishing a successful tract. 
Advances in optics and miniaturization of endo instruments 
have also reduced the morbidity and improved the success rate. 
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Introduction of flexible instruments have also greatly improved 
access into all parts of collecting system without need for 
additional tracts. 
Advances in intracorporeal lithotripters have also improved 
the success rate of percutaneous nephrolithotomy. Smaller size 
lithotripter probes and efficient retrival of stone fragments have 
improved the outcome of the procedure. 
Inspite of all the advances and resultant improvements certain 
morbidities of the procedure continue to affect the patients. Even 
though the procedure is being done under standard antibiotic 
prophylaxis still patients develop postoperative fever. 
The procedure is usually done after sterilizing the urine in 
patients with preoperative urine culture showing growth. Still 15 -
30 % of patients develop postoperative systemic inflammatory 
response syndrome of which 1-2% develop sepsis. The likelihood 
of patients developing sepsis can not be predicted as of now.  
But the likelihood of developing systemic inflammatory 
response syndrome in patients undergoing percutaneous 
nephrolithotomy  can be determined by identifying certain 
preoperative and intraoperative  factors associated with the patients. 
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Our study comprising of 120 patients who underwent 
percutaneous nephrolithotomy showed that 29(24.1%) of them 
developed SIRS postoperatively. A study by Ruslan Korets et al 
showed SIRS incidence of 9.8 %.Another study by Liang Chen et el 
showed SIRS incidence of 23.4%. 
On analysis of data collected before ,during and after surgery 
it showed certain factors associated significantly in developing 
SIRS. 
Univariate analysis showed significant association between 
age of the patient (> 42 years) ,need for blood transfusion, stone 
size (> 2.893 cms), number of access tracts (1 or > 1), operative 
time (> 70 minutes),pelvic urine culture showing growth and stone 
culture showing growth. 
With regard to gender distribution, diabetes mellitus, bladder 
urine culture showing growth and raised serum creatinine the 
association was found to be statistically insignificant. 
On multivariate analysis only stone size, number of access 
tracts, operative time and stone culture were found to be 
statistically significant in predicting occurrence of SIRS 
postoperatively. 
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CONCLUSION 
In patients undergoing percutaneous nephrolithotomy the 
following factors were found on analysis to be significantly associated 
with developing systemic inflammatory response syndrome and 
thereby helping to identify those likely to develop sepsis. 
1) Univariate analysis showed significant association between 
age of the patient blood transfusion, stone size, number of 
access tracts, operative time, pelvic urine culture showing 
growth and stone culture showing growth as predictors of 
SIRS. 
2) Multivariate analysis showed stone size, number of access 
tracts, operative time and stone culture as statistically 
significant in predicting occurrence of SIRS postoperatively. 
3) In this study no statistically significant association was found 
between gender, diabetes mellitus,bladder urine culture and 
raised serum creatinine in developing SIRS postoperatively. 
4) Hence patients with above identified risk factors can be given 
appropriate antibiotics in order to prevent the occurrence of 
sepsis postoperatively. 
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Figure showing antegrade access 
 
Figure showing fluoroscopic guidance 
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Computerized tomography showing renal calculus 
 
Computerized tomography showing renal calculi 
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Nephrostomy drainage post PCNL 
 
Figure showing antegrade access 
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ABBREVIATIONS 
BU           :       Bladder urine. 
CS           :      Culture & sensitivity. 
DM           :       Diabetes mellitus 
PCNL       :  Percutaneous nephrolithotomy. 
PU            :      Pelvic urine. 
SIRS  :     Systemic Inflammatory Response Syndrome. 
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PROFORMA 
NAME                                                       AGE/SEX                                     URO NO 
ADDRESS 
 
 
 
CLINICAL PRESENTATION 
 
            LOIN PAIN                  RIGHT/LEFT 
            FEVER                              YES/NO 
            DYSURIA                         YES/NO 
            PYURIA                            YES/NO 
            CALCULURIA                  YES/NO 
            HEMATURIA                  YES/NO 
 
COMORBID ILLNESS 
            DIABETES/HYPERTENSION/TUBERCULOSIS/CAD. 
 
PREVIOUS UROLOGICAL PROCEDURES 
 
GENERAL EXAMINATION 
           GENERAL CONDITION 
           ANAEMIA 
           TEMPERATURE 
SYSTEMIC EXAMINATION 
          ABDOMEN 
          CARDIOVASCULAR SYSTEM 
          RESPIRATORY SYSTEM 
          EXTERNAL GENITALIA 
BASIC INVESTIGATION 
           URINE ROUTINE 
           BLADDER URINE CULTURE/SENSITIVITY 
           COMPLETE BLOOD COUNT 
           RENAL FUNCTION TEST 
IMAGING 
           PLAIN X RAY KUB 
           ULTRASONOGRAM KUB 
           CONTRAST CT  KUB 
                             STONE SIZE    
                             LOCATION 
INTRA OPERATIVE RECORDINGS 
            NO OF TRACTS 
            OPERATIVE TIME 
            PELVIC URINE C/S 
            STONE C/S 
            STONE ANALYSIS 
POST OPERATIVE RECORDINGS 
           TEMPERATURE 
           PULSE RATE 
           RESPIRATORY RATE 
           WBC COUNT 
           X RAY KUB 
           USG KUB 
          
    
 
 
Sr.
Creatinine DM
Bladder Urine 
C/S
Stone 
Size
No. of 
Tracts
OP 
Time
Pelvic Urine 
C/S
Stone 
C/S Temp PR RR WBC
1 MILANGURANG 43/m 1.2 N S 2.6 1 74 S S N 99 74 15 7800
2 KALIAMOORTHY 63/M 0.8 N G 3 1 82 G G Y 103 98 28 14200
3 KAMALA 53/F 1.1 Y G 2.5 1 65 S S N 98 76 14 7600
4 KUMUDHAVALLI 28/F 1.3 N G 2.6 1 45 S S N 98.4 78 15 8900
5 KISHOREKUMAR 22/M 0.7 N S 2.8 1 43 S S N 98.5 82 16 6700
6 SUSEELA 45/F 0.6 N G 4 1 85 S G N 102 103 18 8000
7 RAVI 30/M 1.3 N G 2.3 2 95 S S Y 99 88 14 5600
8 BASHEER 55/M 1.1 Y G 3.7 1 65 G S N 101 88 14 12800
9 PITCHAI 65/M 1.8 Y G 3.8 1 55 G S N 98.6 75 15 4600
10 PACHIAPPAN 65/M 1.2 Y G 3.6 1 80 S S N 98.8 73 14 6200
11 DEVAKI 32/F 1 N S 2.6 1 45 S S N 99 84 16 8300
12 SUBRAMANI 42/M 0.9 N G 3.8 2 125 S G Y 104 112 19 10800
13 JEGANATHAN 31/M 0.7 N S 2.6 1 65 S S N 98.3 75 13 4700
14 LAKSHMI 42/F 0.8 N S 2.8 1 75 G S N 103 86 20 8800
15 BOOPALAN 48/M 0.9 N G 3.2 1 80 S S N 97.8 84 13 6900
16 SENTHILNATHAN 45/M 0.6 N G 3 1 110 S S N 98.2 76 14 7800
17 DAKSHINAMOORTHY 55/M 2.2 Y S 2.7 1 95 S G Y 98.4 85 16 8600
18 ANNALAKSHMI 45/F 0.7 N G 2.4 1 65 S S N 99 78 14 6800
19 VENKATESAN 23/M 2.4 N G 2.8 2 110 G G Y 101.6 94 28 16200
20 ARUMUGAM 48/M 1.1 N S 3.2 1 55 S S N 99 84 14 7500
21 USHARANI 47/F 1.2 N G 2.8 1 60 G G N 102.4 86 16 14600
22 MUNIYAMMAL 55/F 1.3 N G 3.2 1 115 G S N 98.4 110 20 13800
23 KUMAR 35/M 1.9 N S 2.3 1 65 S S N 98.3 76 12 6200
24 BANUMATHI 37/F 1.2 N G 2.4 1 70 G S N 98.6 76 12 4100
MASTER CHART
Post OperativeAge/ 
Sex
Blood 
transfusionNameS.No
Pre Operative Intra Operative
Sr.
Creatinine DM
Bladder Urine 
C/S
Stone 
Size
No. of 
Tracts
OP 
Time
Pelvic Urine 
C/S
Stone 
C/S Temp PR RR WBC
Post OperativeAge/ 
Sex
Blood 
transfusionNameS.No
Pre Operative Intra Operative
25 JAMUNA 38/F 1 N S 2.6 1 85 S S N 97.5 78 15 5200
26 MAHENDRAN 28/M 0.8 N G 2.8 1 90 S S N 96.8 72 14 6900
27 BEEMAN 58/M 0.6 Y S 3 2 125 S G N 98.7 78 15 5700
28 RAJAGANDHAM 50/F 1 N G 2.6 1 55 S G N 99 76 13 8600
29 SANTHOSH 22/M 1.2 N G 2.4 1 40 S S N 97.9 88 16 7500
30 RAVI 47/M 0.7 N G 2.5 1 65 S S N 98 76 13 9800
31 NEELA 35/F 0.9 N S 2.7 1 70 S S N 99 78 16 6100
32 DAKSHINAMOORTHY 57/M 1.1 Y G 3.4 2 100 S G Y 103.8 88 26 12300
33 SAGADEVAN 62/M 1.9 N S 2.2 1 55 S S N 97.4 72 14 5400
34 YACOB 60/M 1.2 Y G 2.4 1 95 G G N 101.4 86 16 14700
35 SRINIVASAN 45/M 1.3 N G 2.8 1 100 S S N 98.5 81 14 7500
36 RAJAN 49/M 0.7 N S 3.8 1 110 G G N 103.6 96 14 6400
37 ARUMUGAM 62/M 0.9 Y G 2.6 1 55 S S N 97.4 82 13 5100
38 SHANMUGAM 58/M 0.8 N S 2.8 1 65 S S N 98.2 75 13 6400
39 JOTHI 58/F 1.8 Y S 3.3 1 60 S S Y 101.2 88 18 8700
40 POOMATHU 47/F 1 N S 2.4 1 55 S S N 99 78 16 6200
41 DAVAMANI 45/F 1.3 N G 2.8 1 100 S S N 98.6 88 14 4200
42 SAKUNTHALA 51/F 1.4 Y G 2.8 2 95 S G N 100.8 92 17 12800
43 MAHENDRAN 45/M 1.2 N S 3.2 1 65 G S N 99 84 16 7800
44 DHANALAXMI 45/F 1.1 N G 2.2 1 55 S S N 98.1 73 13 9800
45 BOOPALAN 41/M 0.9 Y G 3 2 65 S S N 97.6 75 15 8900
46 DAYALAN 28/M 0.8 N S 2.9 1 70 G S N 98.5 86 13 9700
47 KRISHNAMOORTHY 32/M 0.6 N S 2.8 2 75 S G N 104.4 110 26 14600
48 SOMASUNDARAM 34/M 1.3 N S 2.6 1 55 S S N 99 87 16 6300
49 PONNI 35/F 1.2 N S 2.4 1 100 S S N 97 85 12 4300
Sr.
Creatinine DM
Bladder Urine 
C/S
Stone 
Size
No. of 
Tracts
OP 
Time
Pelvic Urine 
C/S
Stone 
C/S Temp PR RR WBC
Post OperativeAge/ 
Sex
Blood 
transfusionNameS.No
Pre Operative Intra Operative
50 THIRUGNANASAMBANTHAM 40/M 0.6 N S 3.9 1 95 S G Y 101 92 16 8800
51 KALAVANI 18/F 3.4 N G 3.8 2 65 G S N 104.3 112 26 14600
52 AMSA 45/F 1.1 Y G 3.4 1 100 G G N 103.2 98 18 13600
53 RAJAMOHAMMED 30/M 1 N S 4.1 2 70 S S N 100.8 86 14 12600
54 MALAR 52/F 0.7 Y G 2.6 1 55 S S N 98.3 87 12 5600
55 SOUNDARRAJAN 55/M 0.9 Y G 2.6 1 45 S S N 97.7 64 14 7500
56 PERIYASAMY 49/M 2.6 N G 2.4 1 40 S G Y 98 85 13 9300
57 RADHAKRISHNAN 31/M 1 N S 2.8 1 55 G S N 97.6 86 13 5400
58 NALINI 26/F 1.1 N S 2.8 1 90 S S N 98.9 78 15 8700
59 SAMBHANDHAM 59/M 2.6 Y G 3.9 1 80 G G N 103.6 94 14 11600
60 KUMARASAMY 55/M 1.2 Y S 2.7 1 65 S S N 97.8 65 13 8900
61 DAS 35/M 1.3 N G 2.2 1 60 S S N 97.8 86 12 10200
62 VIJAYALAKSHMI 20/F 1 N G 2.8 1 55 G G N 98.4 76 12 9800
63 MANIKANDAN 30/M 0.7 N G 3.2 1 85 S S N 99 74 14 6800
64 MUNUSAMY 33/M 0.8 N G 2.4 1 105 G S N 97.8 73 16 11200
65 RANGAN 57/M 2.7 Y G 2.6 1 90 G G Y 98.9 87 12 5200
66 KATHAYEE 42/F 1.1 N G 2.4 1 85 G S N 99 76 12 8200
67 NEELA 65/F 2.6 Y S 2.8 1 65 S G Y 103.6 96 18 7800
68 DASSAMMAL 48/F 1.2 N S 2.9 1 60 S S N 98 87 15 8600
69 AMEENA 50/F 1.3 Y G 2.8 1 85 S G N 102.4 92 17 9700
70 RANJITHAM 55/F 1.8 Y S 2.8 1 90 G S N 98.7 64 12 8600
71 NANDHINI 20/F 1.4 N G 3 1 55 S S N 98.7 75 13 5600
72 SENTHIL 35/M 0.6 N S 2.8 1 45 G G N 97.9 86 15 9800
73 ABDULRASHEED 37/M 0.7 Y S 2.4 1 75 S S N 101.4 82 16 8200
74 MUTHU 36/M 0.9 N S 2.8 1 60 S S N 99 76 12 6500
Sr.
Creatinine DM
Bladder Urine 
C/S
Stone 
Size
No. of 
Tracts
OP 
Time
Pelvic Urine 
C/S
Stone 
C/S Temp PR RR WBC
Post OperativeAge/ 
Sex
Blood 
transfusionNameS.No
Pre Operative Intra Operative
75 RAJENDRAN 49/M 1.1 Y G 2.4 1 55 S S N 97.8 86 18 5400
76 MOHAMMEDISMAIL 33/M 1.3 N G 3.3 1 55 G S N 98.8 98 13 5700
77 GANDHIMATHI 60/F 2.7 Y G 2.6 1 50 S G Y 98.9 76 14 9800
78 RAHUL 24/M 1.1 N G 2.7 1 60 G S N 99 86 13 7500
79 CORNELIUS 30/M 1 N S 2.4 1 65 S S N 98.9 76 18 10200
80 HARISH 33/M 0.6 N S 3 1 70 G S N 99 76 14 10400
81 ASHOKKUMAR 42/M 2.3 Y G 3.6 1 75 S G N 98 75 15 5600
82 MAHALAXMI 34/F 0.8 N S 2.4 1 80 S S N 99 72 16 8200
83 MEENAKSHISUNDARAM 44/M 1.1 N G 2.8 1 65 G G N 103.8 106 20 12600
84 SUNDARI 28/F 1.2 N G 2.8 1 50 S S N 99 87 15 7300
85 RAJA 43/M 0.8 N S 3.6 1 85 G S N 101.3 98 14 8900
86 SUGUMAR 29/M 1.3 N S 2.4 1 60 G G N 98.7 76 14 9300
87 DHANALAKSHMI 42/F 0.6 N S 2.4 1 65 S S N 97.6 87 16 10700
88 MALAR 52/F 1.1 Y S 2.5 1 90 G S N 98 84 12 7600
89 PRAKASH 42/M 1 N S 2.4 1 60 S S N 98.7 82 14 8700
90 ASOKAN 42/M 1 N G 2.8 1 50 G G N 99 83 16 10900
91 GANESHKUMAR 29/M 0.8 N S 2.4 1 55 S S N 98.6 76 14 9800
92 KAMATCHI 45/F 0.7 Y G 2.8 1 60 G S N 99 82 13 7500
93 SASIKALA 24/F 0.6 N S 5.1 2 90 S G Y 98.9 78 14 8300
94 LOGANATHAN 28/M 1.2 N S 3.2 1 50 G S N 99.4 76 13 7200
95 PONNUSAMY 64/M 3.2 Y G 3.7 1 55 G S Y 100.8 84 14 14400
96 KOWSALYA 46/F 1.3 N S 2.4 1 45 S S N 99 75 14 8700
97 VEERAMMAL 60/F 2.4 Y G 2.8 1 40 S S N 97.4 76 18 8600
98 MUTHU 45/M 1.1 N S 2.6 1 50 G G N 98.6 87 13 8700
99 XAVIER 36/M 0.6 N S 3.1 1 55 S S Y 98 76 15 6500
Sr.
Creatinine DM
Bladder Urine 
C/S
Stone 
Size
No. of 
Tracts
OP 
Time
Pelvic Urine 
C/S
Stone 
C/S Temp PR RR WBC
Post OperativeAge/ 
Sex
Blood 
transfusionNameS.No
Pre Operative Intra Operative
100 LAKSHMI 42/F 0.9 Y G 3.4 1 65 G G N 103.4 110 16 16600
101 ANTONY 36/M 0.8 N G 2.8 1 60 S S N 98 75 12 5300
102 RAVISHANKAR 24/M 1.1 N S 2.6 1 75 G G N 96.8 76 16 8700
103 CHITHRA 26/F 1.2 N S 2.8 1 70 S S N 99 88 17 10900
104 ANNALAKSHMI 31/F 1 N S 4.2 1 80 G S N 101.2 98 16 10400
105 PONNUSAMY 42/M 0.7 Y S 2.4 1 60 G S N 99 76 15 5400
106 ABDULLAH 56/M 2.8 Y S 2.5 1 55 S G N 104.2 110 24 9600
107 JOHN JOSEPH 36/M 0.6 N S 2.8 1 90 S G N 99 87 14 7500
108 RAVEENDRAN 46/M 0.8 N G 4.4 2 110 S S N 101.5 98 18 8200
109 SUBRAMANI 38/M 0.7 N S 2.4 1 50 S G N 98.8 76 14 6500
110 MANICKAM 54/M 3.2 N S 2.6 1 55 G G N 98 76 12 8700
111 SENTHAMARAI 36/F 1.1 N S 3.3 1 65 S G N 101 105 14 6700
112 MANGALAM 42/F 1.2 Y G 2.4 1 50 S G N 98 76 16 8900
113 SENGAM 48/F 1 Y G 2.6 1 45 G S N 99 86 14 8700
114 KANAGAVALLI 36/F 0.6 N G 2.6 1 55 S G N 98 76 16 8400
115 SHANMUGAM 52/M 0.8 N S 3.8 1 80 S G N 103.4 92 16 7800
116 MARAGATHAM 38/M 0.9 Y G 2.8 1 85 G S N 97.6 87 15 8900
117 MARGARET 27/F 1.2 N S 2.4 1 70 G G N 98 76 14 9900
118 KALYANI 62/F 1.1 N S 2.8 1 60 S S N 103.8 99 16 14600
119 MOHAMMED 43/M 1.3 Y S 3.2 1 45 S G N 97.6 66 14 7300
120 JOSEPH 33/M 0.6 N S 3.6 1 75 G S N 97.4 87 15 8300
Y-Yes,   N-No,    G- Growth,   S- Sterile
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INTRODUCTION Urinary stone disease has been known to affect humans since antiquity. The
incidence of stone disease has shown migration with regard to site of stones from lower to upper.
Also even though stone disease is two to three times more common in young adult males in
comparison to females the gender divide is fast disappearing. The prevalence of renal stone disease
is estimated to be varying around 1% to 15%.It was found that the prevalence in males is 10% and in
females is 4% by Soucie et al1.The disease is more common in whites compared to Asians and Afro-
Americans. The peak age incidence of stones is in the fourth to sixth decades of life. Stones are more
common in hot arid...
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